横纹肌溶解症由罗苏伐他汀与恩替卡韦联合引起：一例报告。
Rhabdomyolysis induced by rosuvastatin combined with entecavir: a case report.
机构信息
Department of Infectious Diseases, The First Affiliated Hospital of China Medical University, 155 Nanjing North Street, Shenyang, 110001, Liaoning, China.
出版信息
BMC Infect Dis. 2022 Apr 11;22(1):365. doi: 10.1186/s12879-022-07254-0.
BACKGROUND
Rhabdomyolysis is a serious and potentially life threatening condition that can be caused by drugs. We report a case of acute hepatitis B with rhabdomyolysis after treatment with rosuvastatin and entecavir.
CASE PRESENTATION
A 72-year-old female was admitted to our hospital due to acute hepatitis B infection. She had taken atorvastatin for 3 months before being admitted to our hospital. After being administered entecavir (ETV) and rosuvastatin to replace atorvastatin, she suffered from muscle pain in both lower limbs and was diagnosed with rhabdomyolysis. After discontinuation of the two drugs, the patient's symptoms subsided and creatine kinase levels returned to normal. We hypothesize that the rhabdomyolysis was caused by the combination of rosuvastatin and ETV.
CONCLUSIONS
We suggest that patients who use rosuvastatin and ETV be made aware of the complication of rhabdomyolysis.
背景
横纹肌溶解症是一种严重的、可能危及生命的疾病，可由药物引起。我们报告了一例使用瑞舒伐他汀和恩替卡韦治疗后发生急性乙型肝炎伴横纹肌溶解症的病例。
病例介绍
一名 72 岁女性因急性乙型肝炎感染入院。她在入院前服用阿托伐他汀 3 个月。在改用恩替卡韦（ETV）和瑞舒伐他汀替代阿托伐他汀后，她出现双下肢肌肉疼痛，被诊断为横纹肌溶解症。停用这两种药物后，患者症状缓解，肌酸激酶水平恢复正常。我们推测横纹肌溶解症是由瑞舒伐他汀和 ETV 联合引起的。
结论
我们建议使用瑞舒伐他汀和 ETV 的患者注意横纹肌溶解症的并发症。
Zotero 插件